Improved Disease-Free Survival With Adjuvant Erlotinib in EGFR-Mutant, Early-Stage NSCLC

Tumor Mutational Burden as a Predictor of Response to Immunotherapy

Leading Cause of Death in Follicular Lymphoma Remains Disease Itself

Long-Term Outcomes of Axicabtagene Ciloleucel: ZUMA-1

Biosimilar Cancer Treatment Ontruzant Gets FDA Approval

In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression

Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot

Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years

Effect of Chemotherapy on Prometastatic Extracellular Vesicles Warrants Further Research

Liquid Biopsy of Cerebrospinal Fluid Provides Genomic Info on Brain Tumors

Risk of Rare Blood Cancers Rises After Solid Tumor Chemotherapy

For 22 of 23 solid cancers investigated in a new study, the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia increases after chemotherapy.

SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC

Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.

Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes

Three specific subtypes of multiple myeloma were found to drive higher incidence rates among individuals of African descent.